Refractory Solid Tumors Clinical Trial
Official title:
MyCustom:A Framework for Prospective and Master Protocol Trial of Precise Drug Treatment for Refractory Solid Tumors
The MyCustom study is a investigator initiated trial(IIT), prospective real-world clinical research project, a genetic biomarker-driven "basket" (tissue-type agonistic) study. The target population covers a variety of solid advanced malignant tumors, including but not limited to patients with small cell lung, gastric, prostate, bladder cancer, head and neck squamous carcinoma or lacking effective treatment after standard treatment failure.
The MyCustom study is a investigator initiated trial(IIT), prospective real-world clinical research project, a genetic biomarker-driven "basket" (tissue-type agonistic) study. The target population covers a variety of solid advanced malignant tumors, including but not limited to patients with small cell lung, gastric, prostate, bladder cancer, head and neck squamous carcinoma or lacking effective treatment after standard treatment failure.The overall goal is to develop a more effective research method to test new individualized treatment hypotheses.This study will provide comprehensive theoretical and practical support for individualized custom model in refractory solid tumors.Archival pathology laboratory samples from patients with treatment-refractory advanced solid cancer of any histologic type undergo Next Gene Sequencing(NGS) analysis.Fllowing obtain the raw data of the patient's gene sequencing, the data are analyzed by the auxiliary decision algorithm to obtain the prioritization results of the drugs matched by this patient.The results are subsequently reviewed by the Molecular Tumor Board (MTB), where eligible patients can be treated in treatment substudies.All patients who receive treatment with a drug available in the protocol will be followed for standard efficacy outcomes including clinical efficacy ,clinical safety and exploratory endpoints such as biomarkers for drug response, change in the tumor microenvironment. For some clinical studies, to meet the primary objective, at least 35% of participants had to achieve a PF2S/PFS1 ≥ 1.3 in a sample population of 25 evaluable patients. sample size was calculated using an exact single-stage design for phase II studies with a one-sided type I error of 5% and a power of 90% under the assumption that PF2S/PFS1≥ 1.3 in ≤10% of patients would be clinically irrelevant, while a success rate ≥ 35% would merit further investigation. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00404508 -
A Phase II Study of Epigenetic Therapy to Overcome Chemotherapy Resistance in Refractory Solid Tumors
|
Phase 2 | |
| Completed |
NCT02450136 -
Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors
|
N/A | |
| Completed |
NCT02596503 -
A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
| Completed |
NCT00759928 -
PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT06150365 -
Single Arm Clinical Study on the Safety and Efficacy of Personalized KSX01-TCRT in Patients With Advanced Solid Tumors
|
Early Phase 1 | |
| Completed |
NCT01247168 -
An Open-Label, Dose-Escalation Study of AZD2461
|
Phase 1 | |
| Completed |
NCT00665990 -
Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia
|
Phase 1 | |
| Completed |
NCT02691793 -
Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors
|
Phase 4 | |
| Completed |
NCT02450149 -
Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors
|
N/A | |
| Completed |
NCT02691767 -
Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors
|
N/A | |
| Terminated |
NCT00664586 -
A Phase 1 Continuous Intravenous Infusion Study of Terameprocol (EM-1421) in Subjects With Refractory Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05811975 -
KSX01-TCRT Injection Project in Solid Tumors
|
Early Phase 1 | |
| Completed |
NCT03810742 -
Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors
|
Phase 1 | |
| Terminated |
NCT03096340 -
Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer
|
Phase 1 | |
| Completed |
NCT02450123 -
Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors
|
N/A | |
| Completed |
NCT02383368 -
A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma
|
Phase 1 | |
| Completed |
NCT00394446 -
Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors
|
Phase 1 | |
| Completed |
NCT03052205 -
A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors
|
Phase 1 | |
| Completed |
NCT02482441 -
A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10
|
Phase 1 | |
| Recruiting |
NCT03739827 -
Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
|